Anakinra for corticosteroid-dependent and colchicine-resistant pericarditis: The IRAP (International Registry of Anakinra for Pericarditis) study
暂无分享,去创建一个
Y. Adler | L. Berkson | G. de Luca | L. Dagna | D. Tousoulis | V. Mardigyan | A. Klein | D. Vassilopoulos | E. Pivetta | C. Giustetto | A. Caforio | G. Emmi | G. Lopalco | F. Iannone | L. Cantarini | G. Lazaros | E. Tombetti | A. Brucato | M. Imazio | S. Maestroni | P. Cremer | M. Rinaldi | D. Prisco | R. Marcolongo | A. Andreis | D. Lotan | Jae K. Oh | S. Luis | Marzia De Biasio | G. D. de Ferrari | A. Cercek | Beni Varma | M. De Biasio
[1] Y. Adler,et al. Recurrent pericarditis: still idiopathic? The pros and cons of a well-honoured term , 2018, Internal and Emergency Medicine.
[2] L. Buckley,et al. Interleukin-1 blockade in cardiovascular diseases: a clinical update , 2018, European heart journal.
[3] A. di Lenarda,et al. Management of idiopathic recurrent pericarditis in adults and in children: a role for IL-1 receptor antagonism , 2018, Internal and Emergency Medicine.
[4] L. Buckley,et al. Interleukin-1 Blockade in Cardiovascular Diseases: From Bench to Bedside , 2018, BioDrugs.
[5] Z. Ekinci,et al. Refractory idiopathic recurrent pericarditis: treatment with interleukin-1 receptor antagonist is an option! , 2017, Journal of cardiovascular medicine.
[6] J. Aróstegui,et al. Efficacy of anakinra in an adult patient with recurrent pericarditis and cardiac tamponade as initial manifestations of tumor necrosis factor receptor‐associated periodic syndrome due to the R92Q TNFRSF1A variant , 2017, International journal of rheumatic diseases.
[7] M. Sormani,et al. Effect of Anakinra on Recurrent Pericarditis Among Patients With Colchicine Resistance and Corticosteroid Dependence: The AIRTRIP Randomized Clinical Trial. , 2016, JAMA.
[8] G. Limongelli,et al. Recurrent pericarditis in children and adolescents: a multicentre cohort study , 2016, Journal of cardiovascular medicine.
[9] D. Tousoulis,et al. Anakinra: an emerging option for refractory idiopathic recurrent pericarditis a systematic review of published evidence , 2016, Journal of Cardiovascular Medicine.
[10] K. Swedberg,et al. 2015 ESC Guidelines for the Diagnosis and Management of Pericardial Diseases. , 2015, Revista espanola de cardiologia.
[11] Jeroen J. Bax,et al. 2015 ESC Guidelines for the diagnosis and management of pericardial diseases , 2015, European heart journal.
[12] L. Cooper,et al. Effectiveness and Safety of Anakinra for Management of Refractory Pericarditis. , 2015, The American journal of cardiology.
[13] A. Abbate,et al. Anti-inflammatory therapies in acute coronary syndromes: is IL-1 blockade a solution? , 2015, European heart journal.
[14] M. LeWinter,et al. Clinical practice. Acute pericarditis. , 2014, The New England journal of medicine.
[15] C. Stefanadis,et al. Anakinra for the management of resistant idiopathic recurrent pericarditis. Initial experience in 10 adult cases , 2014, Annals of the rheumatic diseases.
[16] Y. Adler,et al. Efficacy and safety of colchicine for treatment of multiple recurrences of pericarditis (CORP-2): a multicentre, double-blind, placebo-controlled, randomised trial , 2014, The Lancet.
[17] A. Martini,et al. Long-term efficacy of interleukin-1 receptor antagonist (anakinra) in corticosteroid-dependent and colchicine-resistant recurrent pericarditis. , 2014, The Journal of pediatrics.
[18] E. Silvestri,et al. A new case of idiopathic recurrent acute pericarditis due to R104Q mutation in TNFRSF1A successfully treated with anakinra: expanding the questions. , 2014, Clinical and experimental rheumatology.
[19] I. Ceccherini,et al. A novel mutation in the CIAS1/NLRP3 gene associated with an unexpected phenotype of cryopyrin-associated periodic syndromes. , 2014, Clinical and experimental rheumatology.
[20] Y. Adler,et al. A randomized trial of colchicine for acute pericarditis. , 2013, The New England journal of medicine.
[21] M. Camacho-Lovillo,et al. Successful Treatment of Idiopathic Recurrent Pericarditis With Interleukin-1 Receptor Antagonist (Anakinra) , 2013, Pediatric Cardiology.
[22] C. Tsioufis,et al. Successful treatment of adult patients with idiopathic recurrent pericarditis with an interleukin-1 receptor antagonist (anakinra). , 2012, International journal of cardiology.
[23] F. Chiarelli,et al. Efficacy of an Interleukin-1β Receptor Antagonist (Anakinra) in Idiopathic Recurrent Pericarditis , 2012, Pediatric Cardiology.
[24] Y. Adler,et al. Colchicine for Recurrent Pericarditis (CORP) , 2011, Annals of Internal Medicine.
[25] P. Hawkins,et al. A case series and systematic literature review of anakinra and immunosuppression in idiopathic recurrent pericarditis. , 2011, Journal of cardiology cases.
[26] D. Nordström,et al. Injection-site reactions upon Kineret (anakinra) administration: experiences and explanations , 2011, Rheumatology International.
[27] Y. Adler,et al. Colchicine for Recurrent Pericarditis (CORP) , 2011, Annals of Internal Medicine.
[28] Y. Adler,et al. Medical therapy of pericardial diseases: part I: idiopathic and infectious pericarditis. , 2010, Journal of cardiovascular medicine.
[29] R. Cimaz,et al. Recurrent pericarditis caused by a rare mutation in the TNFRSF1A gene and with excellent response to anakinra treatment. , 2010, Clinical and experimental rheumatology.
[30] A. Angelini,et al. Anti-heart and anti-intercalated disk autoantibodies: evidence for autoimmunity in idiopathic recurrent acute pericarditis , 2010, Heart.
[31] M. Dougados,et al. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials , 2008, Annals of the rheumatic diseases.
[32] A. Martini,et al. Successful treatment of idiopathic recurrent pericarditis in children with interleukin-1beta receptor antagonist (anakinra): an unrecognized autoinflammatory disease? , 2009, Arthritis and rheumatism.
[33] G. Brambilla,et al. Corticosteroids for Recurrent Pericarditis: High Versus Low Doses: A Nonrandomized Observation , 2008, Circulation.
[34] S. Pocock,et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies , 2007, The Lancet.